What happens to stocks if AI loses momentum?
NEW YORK - J.P. Morgan SE has announced that no stabilisation actions were taken for the securities offered by Teva Pharmaceutical (NYSE:TEVA) Finance Netherlands IV BV and Teva Pharmaceutical Finance Netherlands III BV. The notice, issued today, follows a pre-stabilisation period announcement made on Sunday.
The securities in question include USD 700 million in 5.5-year and USD 500 million in 7.5-year senior unsecured notes. These notes, denominated in euros, were listed on the New York Stock Exchange and are SEC-registered. The offer prices were reported at 99.418% for the 5.5-year notes and 99.256% for the 7.5-year notes.
Stabilisation measures, which can be employed by financial institutions to support the price of a security after its initial offering, were not deemed necessary by the stabilisation managers. J.P. Morgan SE coordinated the stabilization, with BNP Paribas (OTC:BNPQY), Citibank, and Societe Generale (OTC:SCGLY) serving as stabilisation managers.
The announcement clarifies that the information is intended solely for informational purposes and does not represent an invitation or offer to purchase or dispose of the Issuer’s securities in any jurisdiction.
Investors and market observers note that the absence of stabilisation activities could suggest a stable or satisfactory demand for the securities offered. This event is based on a press release statement and is reported in compliance with market regulations and for the purpose of public disclosure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.